GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), today told the investment community of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine. According to the press release, this completed study represents the first HIV/AIDS vaccine trial to show prevention of infection.
Robert McNally, Ph.D., Chief Executive Officer and President stated, “The results are highly encouraging for the clinical studies of our HIV/AIDS vaccine and we congratulate the Thai ministry of Public Health for successful conduct of a groundbreaking trial that included 16,000 volunteers and was supported by multiple agencies including the U.S. Army and the U.S. National Institutes of Health (NIH).”
“The partial success of this trial is very important to the GeoVax vaccine, because the vaccine tested in Thailand, like the GeoVax vaccine, was designed to elicit both T cells and antibody,” commented Dr. Harriet Robinson, Senior Vice President of Research & Development. “The two vaccines that have failed in previous efficacy trials elicited only antibody or only T cells. This was the first efficacy test of a vaccine that elicited both antibody and T cells and is very encouraging for the GeoVax vaccine, because our vaccine generates higher frequencies of T cells and better quality antibody. Given what we know about the elicited responses observed in this study, and the similarities and differences between our vaccine and the Sanofi-Aventis vaccine, the GeoVax vaccine should be poised for a higher level of protective success than the 30% success rate achieved in Thailand,” noted Dr. Robinson.
“Within the two main areas of focus for our HIV/AIDS vaccine – preventative and therapeutic – we continue to make progress,” added Dr. McNally. “The preventative version of the vaccine has advanced to a Phase 2a human clinical trial, which was initiated in February 2009 by the HIV Vaccine Trials Network (HVTN) and continues to have steadily increasing enrollment. On the therapeutic vaccine, we continue to plan out the details of a Phase 1 human clinical trial and expect to begin this trial, assuming U.S. Food and Drug Administration (FDA) concurrence, in the first quarter of 2010.”